Astellas reports IZERVAY reduced driving eligibility loss risk in eye disease study May 12, 2026 09:04AM
PADCEV plus Keytruda reduces bladder cancer recurrence risk by 47% Feb 27, 2026 10:04AM
Astrellas and Pfizer's (PFE) announces results from Phase 3 study on XTANDI May 22, 2025 05:05PM
Farallon Capital Builds Over 3% Position In Japan's Astellas- FT Feb 12, 2025 12:04AM
Pfizer (PFE) and Astellas PADCEV plus KEYTRUDA Shows Long-Term Efficacy in First-Line Treatment of la/mUC Feb 10, 2025 05:01PM